GLP-1 Safety Center
Your independent safety resource for Ozempic, Wegovy, Mounjaro, and Zepbound. We track FDA enforcement actions, document side effects, verify providers, and follow active litigation so you can make informed decisions about GLP-1 medications.
Side Effects Guide
Comprehensive breakdown of GLP-1 side effects from common GI issues to rare but serious complications. Know what to expect and when to seek help.
Managing Side Effects
Practical, evidence-based strategies for managing common GLP-1 side effects like nausea, constipation, and fatigue. Tips from gastroenterologists and patients.
FDA Safety Alerts
Real-time tracking of FDA warning letters, recalls, and enforcement actions against GLP-1 compounders and distributors.
Lawsuit Tracker
Follow active GLP-1 litigation including class actions against Novo Nordisk and Eli Lilly. Understand the legal landscape.
Scam Checker
Verify if your GLP-1 provider is legitimate. Red flags, green flags, and a step-by-step checklist to protect yourself from fraud.
Ozempic & Pregnancy
Critical safety information about GLP-1 medications and pregnancy. When to stop, waiting periods, fertility effects, and what the FDA recommends.
Warning: Compounded GLP-1 Medications
The FDA declared the semaglutide shortage officially over in February 2025, removing the legal basis for most compounding pharmacies to produce semaglutide copies. Despite this, many compounders continue to sell compounded semaglutide illegally. In March 2026, the FDA escalated enforcement by issuing warning letters to 12 additional compounders.
- The FDA has issued warning letters to 50+ compounders for contamination, incorrect dosing, and use of unapproved salt forms
- Some compounded products have been found to contain dangerously incorrect concentrations of semaglutide
- Compounded medications do not undergo the same quality testing as FDA-approved drugs
- Several patients have reported serious adverse events linked to compounded GLP-1 products
Essential Safety Tips
Verify Your Provider
Always confirm your provider uses state-licensed pharmacies and has verifiable, named physicians on staff.
Start Low, Go Slow
GLP-1 medications should be titrated gradually. Any provider shipping you a high dose immediately is a red flag.
Report Problems
Report adverse events to the FDA MedWatch program and your state pharmacy board. Your report could protect others.
Medicare GLP-1 Coverage Coming July 2026
With Medicare Part D coverage launching in July 2026, millions of seniors will gain access to FDA-approved GLP-1 medications for the first time. This is especially important from a safety perspective — Medicare coverage means access to regulated, brand-name drugs instead of potentially risky compounded alternatives. Read our full Medicare GLP-1 Bridge Program guide to understand eligibility and enrollment.
Not Sure About Your Provider?
Use our scam checker to verify legitimacy, or see our independently ranked providers.